Analyst Price Target is $31.00
▲ +1,043.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Moleculin Biotech in the last 3 months. The average price target is $31.00, with a high forecast of $45.00 and a low forecast of $8.00. The average price target represents a 1,043.91% upside from the last price of $2.71.
Current Consensus is
Buy
The current consensus among 3 polled investment analysts is to buy stock in Moleculin Biotech. This Buy consensus rating has held steady for over two years.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More
